AbbVie Q3 adj. EPS $3.66 (+29.3%) on revenue $14.8B; raises 2023 dividend 5%

AbbVie Inc.

2022-Q3 EPS reported $5.24 revenue$42,933,000,000

GAAP diluted EPS $2.21 (+24.2%); adjusted diluted EPS $3.66 (+29.3%), includes $0.02 IPR&D hit.
Total net revenues $14.812B (+3.3% reported, +5.4% operational). Immunology $7.651B (+14.6%).
U.S. Humira $4.956B (+7.4%); international Humira $603M (-25.9%) due to biosimilars; Skyrizi $1.397B, Rinvoq $695M.
Hematologic oncology $1.650B (-11.7%) with Imbruvica $1.135B (-17.4%); Neuroscience $1.672B (+6.7%), Aesthetics $1.301B (+4.0%).
Narrows FY2022 adj. EPS guidance to $13.84-$13.88 (from $13.76-$13.96); announces 5% dividend increase starting Feb 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AbbVie Inc. reported the third quarter ended September 30, 2022 results: revenue $14.812 Billion, EPS $3.66. Guidance reaffirmed.

Period: the third quarter ended September 30, 2022
Revenue: $14.812 Billion
EPS: $3.66
Guidance: reaffirmed
Result: reported results

Exact text from the filing

• Reports Third-Quarter Diluted EPS of $2.21 on a GAAP Basis, an Increase of 24.2 Percent; Adjusted Diluted EPS of $3.66, an Increase of 29.3 Percent; These Results Include an Unfavorable Impact of $0.02 Per Share related to Acquired IPR&D and Milestones Expense 1 • Delivers Third-Quarter Net Revenues of $14.812 Billion, an Increase of 3.3 Percent on a Reported Basis and 5.4 Percent Operationally

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

AbbVie Inc. filing history →

Source: SEC EDGAR

accession 0001551152-22-000038

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.